VBL Therapeutics to Present at the H.C. Wainwright NASH Investor Conference
March 28 2017 - 7:00AM
VBL Therapeutics (Nasdaq:VBLT), a clinical-stage biotechnology
company focused on the discovery, development and commercialization
of first-in-class treatments for cancer, today announced it will
provide a corporate overview at the H.C. Wainwright 1st Annual NASH
Investor Conference, being held April 3, 2017 at the St. Regis
Hotel in New York City.
VBL
Therapeutics Presentation Details @ H.C. Wainwright NASH Investor
Conference |
Date: |
Monday, April
3 |
Time: |
8:20am Eastern
Time |
Presentation
Room: |
Versailles
Room |
Webcast: |
http://wsw.com/webcast/hcw/vbl |
About VBL's Lecinoxoid Platform: VBL
Therapeutics has developed the Lecinoxoids, a novel class of
orally-available anti-inflammatory small molecules. Lecinoxoids
mimic the structure of native phospholipid molecules that regulate
the inflammatory process in vivo; however, Lecinoxoids are
synthesized chemically in a manner that increases their stability
and ability to target specific receptors. Lecinoxoids act through
two specific mechanisms: (1) The inhibition of the Toll-like
receptor (TLR) signaling by the TLR2 and CD14/TLR4 complexes –
inflammatory pathways implicated in various inflammatory diseases;
and (2) the inhibition of the migration of monocytes toward
chemo-attractants present in areas of inflammation. By modulating
innate immunity, the controller of the immune system, Lecinoxoids
can potentially target a spectrum of immune-inflammatory diseases
including cardiovascular diseases, NASH/Liver fibrosis, renal
fibrosis and others. The lead drug from the Lecinoxoids platform,
VB-201, is an oral small molecule that has been administered to
more than 600 patients, across eight trials and was observed to be
safe. In an exploratory Phase 2 trial, VB-201 has demonstrated
significant reduction of vascular inflammation, meeting the primary
endpoint of the study. VB-201 is Phase-2-ready and can be employed
directly in clinical trials. Beyond VB-201, VBL has developed 2nd
and 3rd generation structurally-related chemical compounds, which
we believe offer greater pharmacological efficacy, higher
mechanistic selectivity and longer patent term relative to VB-201.
We have observed promising preclinical results in NASH and renal
fibrosis models in some molecules, such as VB-201 and VB-703.
About VBL Vascular Biogenics Ltd.,
operating as VBL Therapeutics, is a clinical stage
biopharmaceutical company focused on the discovery, development and
commercialization of first-in-class treatments for cancer. The
Company’s lead oncology product candidate, ofranergene obadenovec
(VB-111), is a first-in-class, targeted anti-cancer gene-therapy
agent that is positioned to treat a wide range of solid tumors. It
is conveniently administered as an IV infusion once every two
months. It has been observed to be well-tolerated in >200 cancer
patients and we have observed its efficacy signals in an “all
comers” Phase 1 trial as well as in three tumor-specific Phase 2
studies. Ofranergene obadenovec is currently being studied in a
Phase 3 pivotal trial for recurrent Glioblastoma, conducted under
an FDA Special Protocol Assessment (SPA).
Forward Looking Statements: This press release
contains forward-looking statements. All statements other than
statements of historical fact are forward-looking statements, which
are often indicated by terms such as “anticipate,” “believe,”
“could,” “estimate,” “expect,” “goal,” “intend,” “look forward to”,
“may,” “plan,” “potential,” “predict,” “project,” “should,” “will,”
“would” and similar expressions. These forward-looking statements
include, but are not limited to, statements regarding the clinical
development of VB-111 and its therapeutic potential and clinical
results, including statements related to the Phase 3 pivotal trial
for rGBM, and statements regarding our Lecinoxoids platform and its
therapeutic potential and clinical results. These forward-looking
statements are not promises or guarantees and involve substantial
risks and uncertainties. Among the factors that could cause actual
results to differ materially from those described or projected
herein include uncertainties associated generally with research and
development, clinical trials and related regulatory reviews and
approvals, and the risk that historical clinical trial results may
not be predictive of future trial results. A further list and
description of these risks, uncertainties and other risks can be
found in the Company's regulatory filings with the U.S.
Securities and Exchange Commission. Existing and prospective
investors are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date hereof.
VBL Therapeutics undertakes no obligation to update or revise the
information contained in this press release, whether as a result of
new information, future events or circumstances or otherwise.
INVESTOR CONTACT:
Michael Rice
LifeSci Advisors, LLC
(646) 597-6979
Vascular Biogenics (NASDAQ:VBLT)
Historical Stock Chart
From Apr 2024 to May 2024
Vascular Biogenics (NASDAQ:VBLT)
Historical Stock Chart
From May 2023 to May 2024